An evaluation of the use of oral bisphosphonates and risk of esophageal cancer;Una evaluación del uso de los bifosfonatos orales y el riego de cáncer esofágico

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 419-423

  Haber, Stacy L ^a   McNatty, Danny ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b BANNER HEALTH   (United States)

Author keywords

Bisphosphonates; Esophageal cancer

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BARRETT ESOPHAGUS; CANCER RISK; DRUG SCREENING; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; GASTROINTESTINAL IRRITATION; HUMAN; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; HUMANS; RISK;

EID: 84858062241     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q482     Document Type: Review

References (20)

1. Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15.
2. Udell JA, Fischer MA, Brookhart MA, Soloman DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006;21:765-71. DOI 10.1359/JBMR.060119
3. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21. DOI 10.1056/NEJM/199610033351403
4. Product information. Fosamax (alendronate). Whitehouse Station, NJ: Merck & Co., January 2011.
5. Product information. Actonel (risedronate). Rockaway, NJ: Warner Chilcott, February 2011.
6. Product information. Boniva (ibandronate). South San Francisco, CA: Roche, January 2011.
7. Product information. Didronel (etidronate disodium). Cincinnati, OH: Procter & Gamble, March, 2010.
8. Product information. Skelid (tiludronate). Bridgewater, NJ: Sanofi-Aven-tis, March, 2010.
9. Ribeiro AR, DeVault, KR, Wolfe J, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47:525-8. DOI 10.1016/S0016-5107(98)70256-1
10. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendro-nate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999;12:1152-7.
11. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphos-phonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341: c4444. DOI 10.1136/bmj.c4444
12. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 2002;50(suppl):v1-v23.
13. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90. DOI 10.1056/NEJMc0808738
14. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1789. DOI 101.1056/NEJMc096026
15. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use (letter). N Engl J Med 2009;360: 1789-90. DOI 101.1056/NEJMc096026
16. Nguyen DM, Schwartz J, Richardson P, El-Serag HB. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci 2010;55:3404-7. DOI 10.1007/s10620-010-1198-1
17. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63. DOI 10.1001/jama.2010.1098
18. Drugs.com. Pharmaceutical sales 2009. www.drugs.com/top200.htm (accessed 2011 Jun 24).
19. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010.
20. US Food and Drug Administration. Oral osteoporosis drugs (bisphosphonates): drug safety communication-potential increased risk of esopha-geal cancer. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm264087.htm (accessed 2011 Aug 3)